Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a

Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup

ATLANTA, April 30, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 14, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sre

Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our outstanding fourth quarter and full year 2023 net revenue of $26.3 million and $80.8 mill

ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants can register for the conference by navigating to https://dp

Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "We are pleased to announce record net revenue of $23.4 million, a significant decrea

ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report third quarter financial results on October 26, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/

Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022Global End User Demand for ILUVIEN Up 13.5% vs. Second Quarter of 2022 ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023. "This was a pivotal quarter for Alimera. We completed a transformational transaction to add YUTIQ to ou

ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments. Following management's formal remarks there will be a question-and-answer session. Participants are asked to pre-register for the call. Please note that registered partici

ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.  "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b

ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr

ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we

ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhney, M.D. to its Board of Directors. Dr. Sawhney is presently the Chief Financial Officer for Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies. Dr. Sawhney will fill the position vacated by long term board member, Dr. Brian K. Halak. "Dr. Sawhney brings a richness of financial experience both from the pharma corporate and healthcare investment

ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President and Chief Financial Officer ("CFO"), effective today, January 9, 2023.  "We are extremely excited to have someone of Russell's caliber join us here at Alimera," said Rick Eiswirth, President and CEO of Alimera. "His extensive tenure in multiple pharma sectors as well as his broad experience in acquisitions and licensing, cap

ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri. "I am very excited that Dr. Dyer is joining our team in this newly created position as he brings the insights of a seasoned practicing retina specialist, and accomplished business owner to Alimera,